[go: up one dir, main page]

MA39009A - Compositions pharmaceutiques comprenant un agent actif - Google Patents

Compositions pharmaceutiques comprenant un agent actif

Info

Publication number
MA39009A
MA39009A MA039009A MA39009A MA39009A MA 39009 A MA39009 A MA 39009A MA 039009 A MA039009 A MA 039009A MA 39009 A MA39009 A MA 39009A MA 39009 A MA39009 A MA 39009A
Authority
MA
Morocco
Prior art keywords
comprenant
agent actif
compositions pharmaceutiques
compositions
pharmaceutiques
Prior art date
Application number
MA039009A
Other languages
English (en)
Original Assignee
Galenicum Health Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galenicum Health Sl filed Critical Galenicum Health Sl
Publication of MA39009A publication Critical patent/MA39009A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant le racécadotril d'agent actif, un procédé pour leur préparation et à leur utilisation dans le traitement de la diarrhée.
MA039009A 2014-03-10 2015-03-09 Compositions pharmaceutiques comprenant un agent actif MA39009A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14158478 2014-03-10

Publications (1)

Publication Number Publication Date
MA39009A true MA39009A (fr) 2015-09-16

Family

ID=50236078

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039009A MA39009A (fr) 2014-03-10 2015-03-09 Compositions pharmaceutiques comprenant un agent actif

Country Status (3)

Country Link
EP (1) EP2918268A1 (fr)
ES (1) ES2549127T1 (fr)
MA (1) MA39009A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128098A1 (fr) * 2015-02-09 2016-08-18 Rivopharm Sa Formulation pharmaceutique de racécadotril
NL2026905B1 (en) * 2020-11-16 2022-06-30 Pharmamatch B V Pharmaceutical granulate formulation and method for the preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
DE4322572A1 (de) 1993-07-07 1995-01-12 Byk Gulden Lomberg Chem Fab Beutelverpackung für flüssige Arzneimittel
ES2247163T3 (es) 2000-06-23 2006-03-01 Bioprojet Formulacion en polvo seca que comprende racedotril.
GB0015490D0 (en) 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
FR2900823B1 (fr) 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
CN102018707A (zh) * 2010-11-29 2011-04-20 昆明邦宇制药有限公司 一种治疗腹泻的药物组合物及其制剂
EP2462922A1 (fr) 2010-12-10 2012-06-13 Bioprojet Nouvelle forme d'administration pour inhibiteurs de l'enképhalinase
CN103565750A (zh) * 2013-09-30 2014-02-12 北京德众万全药物技术开发有限公司 消旋卡多曲颗粒及其制备方法

Also Published As

Publication number Publication date
EP2918268A1 (fr) 2015-09-16
ES2549127T1 (es) 2015-10-23

Similar Documents

Publication Publication Date Title
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
MY187540A (en) Compounds active towards bromodomains
TW201613901A (en) New compounds
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TN2015000278A1 (en) Autotaxin inhibitors
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
IN2014MU00916A (fr)
HK1256174A1 (zh) 用於治疗疼痛的 vap-1 抑制剂
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
ZA201906153B (en) Pharmaceutical compositions for combination therapy